At Mycovia, we are passionate about developing novel drugs in areas of unmet medical need, with an initial focus in women’s health.
Our lead product candidate, VT-1161, is being developed as a treatment for recurrent vulvovaginal candidiasis (RVVC), a debilitating chronic condition that affects millions of women worldwide. More commonly known as a chronic yeast infection, RVVC can severely impact a woman’s physical and emotional well being, and results in billions of dollars in lost productivity.
With no FDA-approved treatments for RVVC in the U.S., there are limited treatment options available for women who experience three or more yeast infections a year. Mycovia currently has three Phase 3 clinical studies being conducted to evaluate VT-1161 for the treatment of RVVC and is on path to be the first FDA-approved treatment for this debilitating disease.
While women’s health remains the company’s primary focus, Mycovia recognizes that there is tremendous potential for oral fungal inhibitors to treat a range of multi-drug resistant fungal pathogens.
VT-1161 has also been studied for the treatment of onychomycosis, a fungal infection of the nail, which affects approximately 35 million people in the United States and millions more around the globe. Onychomycosis can be a significant medical issue particularly for people with diabetes or those who have compromised immune systems or poor circulation of the lower extremities. VT-1161 has completed a Phase 2b trial in onychomycosis and met its primary endpoint of complete cure rates at 48 weeks.
VT-1598 is in Phase 1 development, having shown in vitro and in vivo activity against a range of resistant fungal pathogens that include:
Cryptococcus neoformans, which is responsible for cryptococcal meningitis, a serious infection of the brain and spinal column that can occur in people living with HIV
Coccidioides, which is responsible for coccidioidomycosis (also known as Valley Fever), a fungal infection on the rise in the Southwestern United States
Candida auris, an emerging multi-drug resistant fungal pathogen that presents a serious global health threat
Mycovia Pharmaceuticals was founded in 2018, following the acquisition of Viamet Pharmaceuticals by NovaQuest Capital Management.